BNP (B-type natriuretic peptide) and its sibling marker NT-proBNP can absolutely be elevated in people who do not have heart failure. The list of non-heart-failure causes is long enough that experienced clinicians treat an elevated reading as the start of a diagnostic conversation, not the end of one. Kidney disease, atrial fibrillation, pulmonary embolism, advancing age, acute infections, and even a hard marathon can all push levels well above the cutoffs that guideline documents associate with heart failure. Understanding why requires a brief look at what triggers BNP release in the first place.
What Triggers BNP Release
BNP is produced mainly by heart muscle cells when they are stretched. The ventricles sense increased wall stress and ramp up BNP gene expression in response. Animal studies show that simply inflating a balloon inside the left ventricle to raise wall stress produces a measurable jump in BNP messenger RNA within a couple of hours.1PubMed. Posttranscriptional activation of BNP gene expression in response to increased left ventricular wall stress: role of calcineurin and PKC That stretch signal is the common thread. Heart failure is one reason ventricles get stretched, but anything that raises the pressure or volume load on either side of the heart can do the same thing. A blood clot in the lungs strains the right ventricle. A stiff aortic valve forces the left ventricle to push harder. Rapid heart rhythms overwork both chambers. All of these trigger BNP release through the same wall-stretch pathway, regardless of whether the patient has classical heart failure.
Once released, the precursor molecule is split into the active BNP hormone and the inert fragment NT-proBNP. BNP is cleared from the blood partly by a dedicated clearance receptor and partly by an enzyme called neprilysin, giving it a short half-life. NT-proBNP sticks around longer because it is mainly cleared by the kidneys.2PubMed. NT-ProBNP: the mechanism behind the marker That difference in clearance matters: conditions that impair the kidneys tend to raise NT-proBNP more dramatically than BNP, and conditions that block neprilysin (like certain medications) do the reverse.
Kidney Disease
Reduced kidney function is one of the most common reasons NT-proBNP climbs in someone who does not have heart failure. Because NT-proBNP depends heavily on the kidneys for elimination, falling kidney filtration rates lead to accumulating peptide in the blood. A large study of patients with chronic kidney disease quantified this relationship: for each step down in kidney function, the rise in NT-proBNP grew steeper, and by the most advanced stage of kidney disease the peptide level was roughly three-and-a-half-fold higher than in patients with near-normal kidney function, after adjusting for other factors.3Clinical Kidney Journal. N-terminal pro-B-type natriuretic peptide, eGFR, and progression of kidney disease in chronic kidney disease patients without heart failure That is a substantial bump that has nothing to do with the heart pumping poorly.
The picture gets more complicated because kidney disease and heart disease often coexist. A separate analysis of chronic kidney disease patients found that many cardiac structural features like left ventricular mass and atrial size independently predicted BNP levels, while kidney filtration rate itself did not remain an independent predictor of BNP once those cardiac factors were accounted for.4Scientific Reports. Plasma B-type natriuretic peptide is independently associated with cardiovascular events and mortality in patients with chronic kidney disease In other words, kidney disease raises BNP partly because it genuinely stresses the heart over time, and partly because impaired clearance lets the peptide accumulate. Teasing the two apart in any individual patient is one of the harder puzzles in clinical medicine.
Atrial Fibrillation
Atrial fibrillation, the most common sustained abnormal heart rhythm, is a well-recognized driver of elevated BNP. During atrial fibrillation the atria quiver chaotically, and heart rate often increases, raising the workload on the ventricles. Even in patients specifically confirmed not to have heart failure, permanent or episodic atrial fibrillation was linked to significantly higher BNP levels in the large Breathing Not Properly study.5Journal of the American College of Cardiology. Impact of Atrial Fibrillation on the Diagnostic Performance of B-Type Natriuretic Peptide Concentration in Dyspneic Patients: An Analysis From the Breathing Not Properly Multinational Study This creates a practical headache: a patient shows up short of breath, their BNP is high, and they have atrial fibrillation. Is the BNP elevated because of undiagnosed heart failure, or because of the rhythm disturbance itself? Often, additional imaging is the only way to tell.
Pulmonary Embolism and Pulmonary Hypertension
When a blood clot lodges in the lung arteries, the right ventricle suddenly has to push against much higher resistance. That acute strain causes the right ventricular wall to stretch, and BNP pours out. Studies of acute pulmonary embolism patients have found striking differences: those with right ventricular dysfunction had average BNP levels around 340 to 426 pg/mL, while those without dysfunction averaged only about 39 to 55 pg/mL.6PubMed. B-type natriuretic peptide as an indicator of right ventricular dysfunction in acute pulmonary embolism7PubMed. Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism In this setting, a high BNP does not mean heart failure in the traditional sense. It means the right side of the heart is under acute duress from the clot. Clinicians actually use BNP to gauge how severe the pulmonary embolism is.
A slower version of the same process happens in pulmonary arterial hypertension, where chronically elevated pressure in the lung arteries keeps the right ventricle under continuous strain. BNP levels in these patients track with the severity of pulmonary pressures and resistance, and falling BNP after treatment predicts better survival.8PubMed Central. Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent Chronic lung diseases like COPD can create similar right-sided pressure issues. In patients hospitalized for a COPD flare who had no left ventricular dysfunction, NT-proBNP levels correlated with the estimated pressure in the right ventricle.9PubMed Central. Significance of NT-pro-BNP in acute exacerbation of COPD patients without underlying left ventricular dysfunction
Age, Sex, and Body Composition
Even in completely healthy people, BNP and NT-proBNP vary substantially with age and sex. Both markers rise with advancing age, and women tend to have higher baseline levels than men.10PubMed. Plasma brain natriuretic peptide concentration: impact of age and gender The sex difference appears to be driven by hormonal and body-composition factors.11PubMed Central. Gender-Related Differences in Heart Failure Biomarkers The age effect is particularly dramatic. In one primary-care study establishing reference ranges, about half of the oldest group of healthy subjects had BNP values above the cutoff typically used to screen for heart failure, compared with only about 5% of the youngest group.12PubMed. Age- and gender-specific brain natriuretic peptide (BNP) reference ranges in primary care An elderly patient with a mildly elevated BNP may simply be reflecting normal aging rather than a failing heart.
Obesity flips this problem in the other direction. People with more visceral fat tend to have paradoxically lower BNP levels than you would expect, even when they do have heart failure. Fat cells express higher numbers of the clearance receptor that removes active BNP from the bloodstream, so more body fat means faster elimination.13PubMed. The paradox of low BNP levels in obesity This means that a “normal” BNP in an obese patient can be falsely reassuring, while a mildly elevated BNP in a thin elderly woman might mean nothing at all.
Acute Coronary Ischemia
Heart attacks and unstable angina can elevate BNP even when the heart’s pumping function remains intact. Transient myocardial ischemia, a temporary interruption in blood flow to part of the heart, produces an immediate rise in circulating BNP proportional to the severity of the ischemic episode.14PubMed. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia Research comparing patients with different types of acute coronary syndrome found that NT-proBNP was significantly elevated early on even in patients whose hearts were still squeezing normally, and there was no meaningful correlation between the peptide level and the ejection fraction measured during the acute phase.15Circulation Journal. Difference in Elevation of N-Terminal Pro-BNP and Conventional Cardiac Markers Between Patients With ST Elevation vs Non-ST Elevation Acute Coronary Syndrome The ischemia itself, through a combination of transient wall-motion abnormality, local inflammation, and neurohormonal activation, drives BNP release independently of lasting pump damage.
Brain Injuries
One of the more surprising non-cardiac triggers is subarachnoid hemorrhage, a type of bleeding in the brain. BNP levels rise shortly after the bleed and can surge further during the first week, particularly in patients who go on to develop vasospasm in the brain’s blood vessels.16PubMed. Brain natriuretic peptide and cerebral vasospasm in subarachnoid hemorrhage: Clinical and TCD correlations The mechanism seems to involve a massive burst of sympathetic nervous system activity triggered by the brain injury. That catecholamine storm can temporarily stun the heart muscle, causing transient wall-motion problems and even small areas of damage, which in turn trigger BNP release.17PubMed. Plasma B-type natriuretic peptide levels are associated with early cardiac dysfunction after subarachnoid hemorrhage The heart is not failing in the traditional sense; it is temporarily overwhelmed by signals from a damaged brain. Similar BNP elevations have been observed after other forms of acute brain injury, including large strokes.
Liver Cirrhosis
Advanced liver disease creates a distinctive circulatory pattern: blood vessels in the abdomen dilate, overall blood volume redistributes, and the heart has to work harder to maintain blood pressure. This altered hemodynamic state stretches the heart enough to raise natriuretic peptide levels. In patients with cirrhosis, NT-proBNP levels were significantly higher than in healthy controls, and the sicker the liver (measured by the Child-Pugh score), the higher the peptide climbed.18PubMed Central. NT-proBNP and Echocardiographic Parameters in Liver Cirrhosis: Correlations with Disease Severity Many cirrhosis patients also develop a condition sometimes called “cirrhotic cardiomyopathy,” where the heart muscle is subtly impaired even though it may not meet traditional criteria for heart failure. The elevated BNP in cirrhosis can reflect a mix of volume overload, cardiac remodeling, and impaired clearance through a struggling liver.
Sepsis and Systemic Inflammation
Severe infections and sepsis are well-documented causes of elevated natriuretic peptides, even when echocardiography shows the heart is pumping fine. Case reports have described markedly elevated NT-proBNP levels in septic patients whose cardiac imaging showed no evidence of myocardial dysfunction.19PubMed Central. Nonheart failure-associated elevation of amino terminal pro-brain natriuretic peptide in the setting of sepsis Several mechanisms likely contribute: inflammatory molecules can directly stimulate BNP production by heart cells, sepsis-related fever and rapid heart rate increase cardiac workload, and cytokines alter vascular tone and fluid distribution. For clinicians in the intensive care unit, this means a high BNP in a septic patient cannot automatically be taken as evidence of heart failure on top of the infection.
Endurance Exercise
Healthy athletes sometimes get a jolt when their post-race lab work shows elevated cardiac markers. After prolonged strenuous exercise like marathon running, BNP and NT-proBNP commonly rise.20PubMed. Independent elevations of N-terminal pro-brain natriuretic peptide and cardiac troponins in endurance athletes after prolonged strenuous exercise A study using cardiac MRI before and after a marathon found that while BNP went up significantly, the left ventricle’s pumping fraction was unchanged and there was no sign of ischemic damage to any heart chamber. What did happen was that the right atrium and right ventricle temporarily dilated and the right ventricular ejection fraction dipped.21PubMed. Acute cardiac effects of marathon running The BNP release in this context appears to be a protective response to short-term cardiac volume overload, not a sign of disease. Levels typically return to normal within a day or two.
Structural Heart Disease Without Pump Failure
Heart valve problems like aortic stenosis can raise BNP long before the heart muscle actually begins to fail. The narrowed valve forces the left ventricle to generate much higher pressures, which thickens the wall over time. BNP levels correlate strongly with the degree of that thickening: patients with aortic stenosis and left ventricular hypertrophy had BNP levels that tracked with heart muscle mass, the pressure gradient across the valve, and the type of remodeling pattern present.22PubMed. Brain natriuretic peptide as a marker of left ventricular hypertrophy in patients with aortic stenosis NT-proBNP was already elevated even with mild degrees of hypertrophy.23PubMed. Natriuretic peptides in patients with aortic stenosis In aortic stenosis patients, both the systolic and diastolic load on the heart contribute to BNP production, supporting the idea that myocardial stretch drives the signal rather than pump failure per se.24PubMed. Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy
Medications That Muddy the Picture
One drug in particular has reshaped how clinicians interpret BNP: sacubitril/valsartan, a combination medication widely used to treat heart failure. The sacubitril component works by blocking neprilysin, the enzyme that breaks down active BNP. The intended therapeutic effect is to let more BNP circulate, because BNP itself lowers blood pressure, reduces fluid retention, and protects the heart. But blocking that clearance enzyme means measured BNP levels go up even as the patient is clinically improving.25PubMed. BNP and NT-proBNP Interpretation in the Neprilysin Inhibitor Era
In the landmark PARADIGM-HF trial, about one in five patients on sacubitril/valsartan saw their BNP level double within the first couple of months of treatment, and about one in sixteen saw it triple.26PubMed Central. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial Meanwhile, NT-proBNP, which is not broken down by neprilysin, tended to fall. The practical takeaway: for any patient taking sacubitril/valsartan, BNP is unreliable as a monitoring tool and NT-proBNP should be used instead. The changes in BNP across different lab assays were also inconsistent, adding another layer of complexity.27PubMed. Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays
Lab Artifacts and False Positives
Occasionally, BNP results are not just misleading but flatly wrong because of interference in the lab assay itself. BNP is measured using immunoassays, and certain substances in a patient’s blood can fool these tests. The most notorious culprits are heterophilic antibodies and human anti-mouse antibodies. These are immune proteins that some people naturally carry; they can bridge the test components and generate a signal even when BNP is not actually present in unusual amounts.
One striking case report described a man with diabetes whose BNP came back above 4,000 pg/mL, a level that would suggest severe heart failure. His heart was pumping normally with an ejection fraction of 62%, and his NT-proBNP, measured by a different kind of assay, was completely normal. The cause turned out to be human anti-mouse antibody interference.28PubMed Central. Extreme Heterophilic Antibody Interference in BNP Immunoassay: A Case Report and Systematic Investigation Protocol Similar cases have been documented across multiple assay platforms, including one series of eight patients whose false-positive results were attributed to heterophilic antibodies or rheumatoid factor.29PubMed Central. Falsely high B-type natriuretic peptide concentration in patients without heart failure attributed to AxSYM assay: case series of eight subjects When a sky-high BNP does not match the clinical picture, the simplest cross-check is to measure NT-proBNP on a different platform. If the two markers wildly disagree, assay interference should be suspected.
The Gray Zone and Why It Matters
Guideline documents for heart failure diagnosis often cite specific BNP and NT-proBNP cutoffs, with values below one threshold considered unlikely to reflect heart failure and values above another threshold considered likely. The range in between is known as the gray zone. A substantial number of patients fall into it, and many of those patients do not have heart failure at the time of testing. But even in people without a prior heart failure diagnosis, gray-zone NT-proBNP readings carry real prognostic weight. In one study following emergency department patients with no known heart failure, those with gray-zone values were far more likely to be hospitalized for heart failure or to die during the follow-up period compared with those whose values were clearly below the threshold.30Revista Española de Cardiología (English Edition). Gray zone NT-proBNP values and long-term outcomes in emergency department patients without prior heart failure
This means that an elevated BNP without current heart failure is not necessarily a clean bill of health. It may reflect one of the many non-cardiac causes discussed above, or it may be an early warning that the heart is under more stress than imaging currently reveals. The clinical context always dictates the next step: a mildly elevated BNP in a 75-year-old woman with normal kidney function and no symptoms probably needs nothing more than monitoring, while the same number in a 50-year-old man with new shortness of breath and atrial fibrillation warrants echocardiography and close follow-up.
Conditions That Suppress BNP
While most of this discussion focuses on what falsely raises BNP, the reverse problem also exists and deserves mention. Obesity, as noted earlier, suppresses BNP through increased clearance. Pericardial effusion, a buildup of fluid around the heart, can also keep BNP misleadingly low because the external fluid pressure prevents the ventricular wall from stretching normally, muting the signal that would otherwise trigger BNP release. In the early minutes after the onset of an acute coronary event, BNP may not yet have risen enough to be detected, creating a window where the test can miss a genuine cardiac emergency. Clinicians who rely on BNP as a one-size-fits-all rule-out tool risk being fooled in both directions, by false highs from non-cardiac causes and by false lows from conditions that blunt the signal.